Randomised phase II trial of S-1 plus oxaliplatin vs S-1 in patients with gemcitabine-refractory pancreatic cancer

S. Ohkawa, T. Okusaka, H. Isayama, A. Fukutomi, K. Yamaguchi, M. Ikeda, A. Funakoshi, M. Nagase, Yasuo Hamamoto, S. Nakamori, Y. Tsuchiya, H. Baba, H. Ishii, Y. Omuro, M. Sho, S. Matsumoto, N. Yamada, H. Yanagimoto, M. Unno, Y. IchikawaS. Takahashi, G. Watanabe, G. Wakabayashi, N. Egawa, M. Tsuda, R. Hosotani, C. Hamada, I. Hyodo

Research output: Contribution to journalArticle

32 Citations (Scopus)

Abstract

Background:This randomised, open-label, multicenter phase II study compared progression-free survival (PFS) of S-1 plus oxaliplatin (SOX) with that of S-1 alone in patients with gemcitabine-refractory pancreatic cancer.Methods:Patients with confirmed progressive disease following the first-line treatment with a gemcitabine-based regimen were randomised to receive either S-1 (80/100/120 mg day -1 based on body surface area (BSA), orally, days 1-28, every 6 weeks) or SOX (S-1 80/100/120 mg day -1 based on BSA, orally, days 1-14, plus oxaliplatin 100 mg m -2, intravenously, day 1, every 3 weeks). The primary end point was PFS.Results:Between January 2009 and July 2010, 271 patients were randomly allocated to either S-1 (n=135) or SOX (n=136). Median PFS for S-1 and SOX were 2.8 and 3.0 months, respectively (hazard ratio (HR)=0.84; 95% confidence interval (CI), 0.65-1.08; stratified log-rank test P=0.18). Median overall survival (OS) was 6.9 vs 7.4 months (HR=1.03; 95% CI, 0.79-1.34; stratified log-rank test P=0.82). The response rate (RR) was 11.5% vs 20.9% (P=0.04). The major grade 3/4 toxicities (S-1 and SOX) were neutropenia (11.4% and 8.1%), thrombocytopenia (4.5% and 10.3%) and anorexia (12.9% and 14.7%).Conclusions:Although SOX showed an advantage in RR, it provided no significant improvement in PFS or OS compared with S-1 alone.

Original languageEnglish
Pages (from-to)1428-1434
Number of pages7
JournalBritish Journal of Cancer
Volume112
Issue number9
DOIs
Publication statusPublished - 2015 Apr 28

Fingerprint

oxaliplatin
gemcitabine
Pancreatic Neoplasms
Disease-Free Survival
Body Surface Area
Confidence Intervals
Survival
Anorexia
Neutropenia
Thrombocytopenia

Keywords

  • chemotherapy
  • oxaliplatin
  • pancreatic cancer
  • S-1
  • SOX

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

Ohkawa, S., Okusaka, T., Isayama, H., Fukutomi, A., Yamaguchi, K., Ikeda, M., ... Hyodo, I. (2015). Randomised phase II trial of S-1 plus oxaliplatin vs S-1 in patients with gemcitabine-refractory pancreatic cancer. British Journal of Cancer, 112(9), 1428-1434. https://doi.org/10.1038/bjc.2015.103

Randomised phase II trial of S-1 plus oxaliplatin vs S-1 in patients with gemcitabine-refractory pancreatic cancer. / Ohkawa, S.; Okusaka, T.; Isayama, H.; Fukutomi, A.; Yamaguchi, K.; Ikeda, M.; Funakoshi, A.; Nagase, M.; Hamamoto, Yasuo; Nakamori, S.; Tsuchiya, Y.; Baba, H.; Ishii, H.; Omuro, Y.; Sho, M.; Matsumoto, S.; Yamada, N.; Yanagimoto, H.; Unno, M.; Ichikawa, Y.; Takahashi, S.; Watanabe, G.; Wakabayashi, G.; Egawa, N.; Tsuda, M.; Hosotani, R.; Hamada, C.; Hyodo, I.

In: British Journal of Cancer, Vol. 112, No. 9, 28.04.2015, p. 1428-1434.

Research output: Contribution to journalArticle

Ohkawa, S, Okusaka, T, Isayama, H, Fukutomi, A, Yamaguchi, K, Ikeda, M, Funakoshi, A, Nagase, M, Hamamoto, Y, Nakamori, S, Tsuchiya, Y, Baba, H, Ishii, H, Omuro, Y, Sho, M, Matsumoto, S, Yamada, N, Yanagimoto, H, Unno, M, Ichikawa, Y, Takahashi, S, Watanabe, G, Wakabayashi, G, Egawa, N, Tsuda, M, Hosotani, R, Hamada, C & Hyodo, I 2015, 'Randomised phase II trial of S-1 plus oxaliplatin vs S-1 in patients with gemcitabine-refractory pancreatic cancer', British Journal of Cancer, vol. 112, no. 9, pp. 1428-1434. https://doi.org/10.1038/bjc.2015.103
Ohkawa, S. ; Okusaka, T. ; Isayama, H. ; Fukutomi, A. ; Yamaguchi, K. ; Ikeda, M. ; Funakoshi, A. ; Nagase, M. ; Hamamoto, Yasuo ; Nakamori, S. ; Tsuchiya, Y. ; Baba, H. ; Ishii, H. ; Omuro, Y. ; Sho, M. ; Matsumoto, S. ; Yamada, N. ; Yanagimoto, H. ; Unno, M. ; Ichikawa, Y. ; Takahashi, S. ; Watanabe, G. ; Wakabayashi, G. ; Egawa, N. ; Tsuda, M. ; Hosotani, R. ; Hamada, C. ; Hyodo, I. / Randomised phase II trial of S-1 plus oxaliplatin vs S-1 in patients with gemcitabine-refractory pancreatic cancer. In: British Journal of Cancer. 2015 ; Vol. 112, No. 9. pp. 1428-1434.
@article{86d687258465481f8f4757b61ddf46c9,
title = "Randomised phase II trial of S-1 plus oxaliplatin vs S-1 in patients with gemcitabine-refractory pancreatic cancer",
abstract = "Background:This randomised, open-label, multicenter phase II study compared progression-free survival (PFS) of S-1 plus oxaliplatin (SOX) with that of S-1 alone in patients with gemcitabine-refractory pancreatic cancer.Methods:Patients with confirmed progressive disease following the first-line treatment with a gemcitabine-based regimen were randomised to receive either S-1 (80/100/120 mg day -1 based on body surface area (BSA), orally, days 1-28, every 6 weeks) or SOX (S-1 80/100/120 mg day -1 based on BSA, orally, days 1-14, plus oxaliplatin 100 mg m -2, intravenously, day 1, every 3 weeks). The primary end point was PFS.Results:Between January 2009 and July 2010, 271 patients were randomly allocated to either S-1 (n=135) or SOX (n=136). Median PFS for S-1 and SOX were 2.8 and 3.0 months, respectively (hazard ratio (HR)=0.84; 95{\%} confidence interval (CI), 0.65-1.08; stratified log-rank test P=0.18). Median overall survival (OS) was 6.9 vs 7.4 months (HR=1.03; 95{\%} CI, 0.79-1.34; stratified log-rank test P=0.82). The response rate (RR) was 11.5{\%} vs 20.9{\%} (P=0.04). The major grade 3/4 toxicities (S-1 and SOX) were neutropenia (11.4{\%} and 8.1{\%}), thrombocytopenia (4.5{\%} and 10.3{\%}) and anorexia (12.9{\%} and 14.7{\%}).Conclusions:Although SOX showed an advantage in RR, it provided no significant improvement in PFS or OS compared with S-1 alone.",
keywords = "chemotherapy, oxaliplatin, pancreatic cancer, S-1, SOX",
author = "S. Ohkawa and T. Okusaka and H. Isayama and A. Fukutomi and K. Yamaguchi and M. Ikeda and A. Funakoshi and M. Nagase and Yasuo Hamamoto and S. Nakamori and Y. Tsuchiya and H. Baba and H. Ishii and Y. Omuro and M. Sho and S. Matsumoto and N. Yamada and H. Yanagimoto and M. Unno and Y. Ichikawa and S. Takahashi and G. Watanabe and G. Wakabayashi and N. Egawa and M. Tsuda and R. Hosotani and C. Hamada and I. Hyodo",
year = "2015",
month = "4",
day = "28",
doi = "10.1038/bjc.2015.103",
language = "English",
volume = "112",
pages = "1428--1434",
journal = "British Journal of Cancer",
issn = "0007-0920",
publisher = "Nature Publishing Group",
number = "9",

}

TY - JOUR

T1 - Randomised phase II trial of S-1 plus oxaliplatin vs S-1 in patients with gemcitabine-refractory pancreatic cancer

AU - Ohkawa, S.

AU - Okusaka, T.

AU - Isayama, H.

AU - Fukutomi, A.

AU - Yamaguchi, K.

AU - Ikeda, M.

AU - Funakoshi, A.

AU - Nagase, M.

AU - Hamamoto, Yasuo

AU - Nakamori, S.

AU - Tsuchiya, Y.

AU - Baba, H.

AU - Ishii, H.

AU - Omuro, Y.

AU - Sho, M.

AU - Matsumoto, S.

AU - Yamada, N.

AU - Yanagimoto, H.

AU - Unno, M.

AU - Ichikawa, Y.

AU - Takahashi, S.

AU - Watanabe, G.

AU - Wakabayashi, G.

AU - Egawa, N.

AU - Tsuda, M.

AU - Hosotani, R.

AU - Hamada, C.

AU - Hyodo, I.

PY - 2015/4/28

Y1 - 2015/4/28

N2 - Background:This randomised, open-label, multicenter phase II study compared progression-free survival (PFS) of S-1 plus oxaliplatin (SOX) with that of S-1 alone in patients with gemcitabine-refractory pancreatic cancer.Methods:Patients with confirmed progressive disease following the first-line treatment with a gemcitabine-based regimen were randomised to receive either S-1 (80/100/120 mg day -1 based on body surface area (BSA), orally, days 1-28, every 6 weeks) or SOX (S-1 80/100/120 mg day -1 based on BSA, orally, days 1-14, plus oxaliplatin 100 mg m -2, intravenously, day 1, every 3 weeks). The primary end point was PFS.Results:Between January 2009 and July 2010, 271 patients were randomly allocated to either S-1 (n=135) or SOX (n=136). Median PFS for S-1 and SOX were 2.8 and 3.0 months, respectively (hazard ratio (HR)=0.84; 95% confidence interval (CI), 0.65-1.08; stratified log-rank test P=0.18). Median overall survival (OS) was 6.9 vs 7.4 months (HR=1.03; 95% CI, 0.79-1.34; stratified log-rank test P=0.82). The response rate (RR) was 11.5% vs 20.9% (P=0.04). The major grade 3/4 toxicities (S-1 and SOX) were neutropenia (11.4% and 8.1%), thrombocytopenia (4.5% and 10.3%) and anorexia (12.9% and 14.7%).Conclusions:Although SOX showed an advantage in RR, it provided no significant improvement in PFS or OS compared with S-1 alone.

AB - Background:This randomised, open-label, multicenter phase II study compared progression-free survival (PFS) of S-1 plus oxaliplatin (SOX) with that of S-1 alone in patients with gemcitabine-refractory pancreatic cancer.Methods:Patients with confirmed progressive disease following the first-line treatment with a gemcitabine-based regimen were randomised to receive either S-1 (80/100/120 mg day -1 based on body surface area (BSA), orally, days 1-28, every 6 weeks) or SOX (S-1 80/100/120 mg day -1 based on BSA, orally, days 1-14, plus oxaliplatin 100 mg m -2, intravenously, day 1, every 3 weeks). The primary end point was PFS.Results:Between January 2009 and July 2010, 271 patients were randomly allocated to either S-1 (n=135) or SOX (n=136). Median PFS for S-1 and SOX were 2.8 and 3.0 months, respectively (hazard ratio (HR)=0.84; 95% confidence interval (CI), 0.65-1.08; stratified log-rank test P=0.18). Median overall survival (OS) was 6.9 vs 7.4 months (HR=1.03; 95% CI, 0.79-1.34; stratified log-rank test P=0.82). The response rate (RR) was 11.5% vs 20.9% (P=0.04). The major grade 3/4 toxicities (S-1 and SOX) were neutropenia (11.4% and 8.1%), thrombocytopenia (4.5% and 10.3%) and anorexia (12.9% and 14.7%).Conclusions:Although SOX showed an advantage in RR, it provided no significant improvement in PFS or OS compared with S-1 alone.

KW - chemotherapy

KW - oxaliplatin

KW - pancreatic cancer

KW - S-1

KW - SOX

UR - http://www.scopus.com/inward/record.url?scp=84928769997&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84928769997&partnerID=8YFLogxK

U2 - 10.1038/bjc.2015.103

DO - 10.1038/bjc.2015.103

M3 - Article

C2 - 25880004

AN - SCOPUS:84928769997

VL - 112

SP - 1428

EP - 1434

JO - British Journal of Cancer

JF - British Journal of Cancer

SN - 0007-0920

IS - 9

ER -